Corynebacterium accolens
Selected indexed studies
- Corynebacterium accolens inhibits Staphylococcus aureus induced mucosal barrier disruption. (Front Microbiol, 2022) [PMID:36187946]
- Corynebacterium accolens-associated pelvic osteomyelitis. (J Clin Microbiol, 2010) [PMID:20032254]
- Corrigendum: Corynebacterium accolens inhibits Staphylococcus aureus induced mucosal barrier disruption. (Front Microbiol, 2023) [PMID:37727292]
_Worker-drafted node — pending editorial review._
Connections
Corynebacterium accolens helps
Corynebacterium accolens is a risk factor for
Sources
- Corynebacterium accolens inhibits Staphylococcus aureus induced mucosal barrier disruption. (2022) pubmed
- Corynebacterium accolens-associated pelvic osteomyelitis. (2010) pubmed
- Corrigendum: Corynebacterium accolens inhibits Staphylococcus aureus induced mucosal barrier disruption. (2023) pubmed
- Corynebacterium accolens Has Antimicrobial Activity against Staphylococcus aureus and Methicillin-Resistant S. aureus Pathogens Isolated from the Sinonasal Niche of Chronic Rhinosinusitis Patients. (2021) pubmed
- Corynebacterium accolens Releases Antipneumococcal Free Fatty Acids from Human Nostril and Skin Surface Triacylglycerols. (2016) pubmed
- Specific nasopharyngeal Corynebacterium strains serve as gatekeepers against SARS-CoV-2 infection. (2023) pubmed
- Corynebacterium accolens isolated from breast abscess: possible association with granulomatous mastitis. (2007) pubmed
- The Brief Case: Ventilator-Associated Corynebacterium accolens Pneumonia in a Patient with Respiratory Failure Due to COVID-19. (2021) pubmed
- Corynebacterium Species Inhibit Streptococcus pneumoniae Colonization and Infection of the Mouse Airway. (2021) pubmed
- In vitro and in vivo evaluation of probiotic properties of Corynebacterium accolens isolated from the human nasal cavity. (2022) pubmed